title: Level of TNF-related apoptosis-inducing-ligand and CXCL8 correlated with 2-[18F]Fluoro-2-deoxy-D-glucose uptake in anti-VEGF treated colon cancers.
abstract: BACKGROUND
  The changes and correlations of TRAIL (TNF-related apoptosis-inducing-ligand) and CXCL8 (IL8) prior to treatment and three months following therapy as well as the corresponding Positron emission tomography (PET/CT) (SUV(max): standardized uptake maximum values) results were evaluated.
  
  
  METHODS
  The measurements were taken before and after treatment for comparison purposes. The study population comprised 29 patients with Metastatic Colorectal cancer (MCRC), undergoing PET/CT scanning prior to treatment.
  
  
  RESULTS
  There were significant changes prior to treatment and three months later for sTRAIL (p=0.0080) and CXCL8 (p=0.0001)values. Generally, sTRAIL values were increasing during therapy, while a decrease was observed for CXCL8. Correlation analysis was applied to the data and revealed significant correlations for the SUV(max) in the primary tumor prior to treatment and CXCL8 prior to therapy (p=0.0303). Furthermore, significant correlations were observed for the SUV(max) and sTRAIL (p=0.0237) as well as CXCL8 (p=0.0002) three months after treatment initiation. CXCL8 prior to treatment was also correlated with the SUV three months after onset of treatment (p=0.0072). A significant correlation was noted for one combination of two variables, the SUV(max) in the metastases and CXCL8 prior to treatment (p=0.0175). These results are supported when we group the SUV(max) in the metastases following treatment into two groups with SUV(max) <5 and SUV(max) >5.
  
  
  CONCLUSIONS
  This study provides evidence that proteomics patterns of sTRAIL and CXCL8 predict tumor response und survival in MCRC patients treated with bevacizumab and within a high concordance of FDG-PET/CT findings.
authors.affiliation: Department of Pathology, Antalya Education and Research Hospital, Antalya, Turkey.
authors.forename: Betül
authors.initials: B
authors.lastname: Celik
authors.forename: Arzu Didem
authors.initials: AD
authors.lastname: Yalcin
authors.forename: Atil
authors.initials: A
authors.lastname: Bisgin
authors.forename: Antonia
authors.initials: A
authors.lastname: Dimitrakopoulou-Strauss
authors.forename: Aysegül
authors.initials: A
authors.lastname: Kargi
authors.forename: Ludwig G
authors.initials: LG
authors.lastname: Strauss
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068258:Bevacizumab; D003110:Colonic Neoplasms / Q000097:blood* / Q000188:drug therapy; D005462:Fluorine Radioisotopes / Q000493:pharmacokinetics; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D006801:Humans; D016209:Interleukin-8 / Q000097:blood*; D049268:Positron-Emission Tomography; D040901:Proteomics; D018709:Statistics, Nonparametric; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000097:blood*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C508606:CXCL8 protein, human; D005462:Fluorine Radioisotopes; D016209:Interleukin-8; D053221:TNF-Related Apoptosis-Inducing Ligand; C505653:TNFSF10 protein, human; D019788:Fluorodeoxyglucose F18; D000068258:Bevacizumab